Cantor Fitzgerald’s Aardvark Therapeutics AARD Stock Holding History

Cantor Fitzgerald’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$672K	Buy	116,582 +49,900	+75%	+$233K	0.01%	261
2026 Q1	$251K	Sell	66,682 -25,000	-27%	-$259K	﹤0.01%	251
2025 Q4	$1.2M	Sell	91,682 -5,000	-5%	-$62.4K	0.02%	153
2025 Q3	$1.28M	Buy	96,682 +20,000	+26%	+$226K	0.01%	194
2025 Q2	$1.04M	Buy	76,682 +10,000	+15%	+$103K	0.02%	154
2025 Q1	$501K	Buy	+66,682	New	+$749K	0.01%	154

Other funds holding AARD

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cantor Fitzgerald's AARD Position: Q2 2026 in Review

Cantor Fitzgerald increased its Aardvark Therapeutics (AARD) stake by 75% in Q2 2026, buying an estimated $233K and bringing the position to 116,582 shares worth $672K. The position accounts for 0.01% of the portfolio, ranked #261.

Cantor Fitzgerald first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.28M in Q3 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

Cantor Fitzgerald held 116,582 shares of Aardvark Therapeutics worth $672K as of Q2 2026.
Cantor Fitzgerald bought 49,900 Aardvark Therapeutics shares in Q2 2026, an estimated $233K.
Aardvark Therapeutics made up 0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #261 holding.
Cantor Fitzgerald first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
Cantor Fitzgerald's Aardvark Therapeutics position peaked at $1.28M in Q3 2025.
71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.